American Association for Cancer Research
Browse
- No file added yet -

Figure S5 from Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction

Download (207.9 kB)
journal contribution
posted on 2023-04-04, 02:04 authored by David C. Florian, Natalie E. Bennett, Mateusz Odziomek, Jessalyn J. Baljon, Mohamed Wehbe, Alyssa R. Merkel, Melissa A. Fischer, Michael R. Savona, Julie A. Rhoades, Scott A. Guelcher, John T. Wilson

Supplementary Figure 5: TRAP+ Osteoclasts in treated versus untreated tibiae.

Funding

U.S. Department of Veterans Affairs (VA)

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

National Science Foundation (NSF)

HHS | NIH | National Cancer Institute (NCI)

Susan G. Komen (SGK)

EIF | Stand Up To Cancer (SU2C)

Incyte (Incyte Corp)

History

ARTICLE ABSTRACT

Bone metastases are difficult to treat due to the inaccessibility of the bone marrow compartment and the immunosuppressive microenvironment that protects resident stem cells. Packaging a STING agonist into a nanoparticle that enables systemic administration and drug accumulation at tumor sites overcomes both barriers to stymie metastatic breast cancer growth.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Nanoparticle AgentsImmunotherapyProgression, Invasion & MetastasisInflammation and tumor developmentBreast Cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC